Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen(KU Leuven), Eric Orwoll(Oregon Health & Science University), Richard Witvrouw(Ziekenhuis Oost-Limburg), Elodie Incera(Novartis (Switzerland)), Oscar Antúnez, Jean‐Yves Reginster(King Saud University), Frank Claessens(KU Leuven), Hans Peter Dimai(Medical University of Graz), Christina Bucci‐Rechtweg, Kurt Lippuner(University of Bern), Dirk Vanderschueren(KU Leuven), Bente Langdahl(Aarhus University Hospital), Erik Fink Eriksen(Osteoporosis Canada), Jean‐Marc Kaufman(Ghent University Hospital), René Rizzoli(University Hospital of Geneva), Josef Hruska(Novartis (Switzerland)), Guoqin Su(Novartis (Switzerland)), Kim Brixen, P. Papanastasiou(Novartis (Switzerland)), Stanley Lipschitz, Luis Augusto Tavares Russo, José Zanchetta(Universidad del Salvador)
Cited by 361
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k